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Background: Fatigue in combination with gait and balance impairments can severely limit daily activities in people
with multiple sclerosis (PWMS). Generalised fatigue has a major impact on walking ability, with moderately disabled
PWMS experiencing difficulty in walking extended distances. Localised motor fatigue in the ankle dorsiflexors can
lead to foot drop, further reducing functional ambulation. The aim of this study is to evaluate the effect of a simple
dynamic dorsiflexion assist orthosis on walking-induced fatigue, gait, balance and functional mobility in PWMS.
Methods: A randomised cross-over trial will be conducted with 40 community dwelling PWMS with mild to
moderate mobility disability. Participants will initially be screened for disease severity, balance, strength, depression
and fatigue at the South Australian Motion Analysis Centre. On two non-consecutive occasions, within two weeks,
participants will undergo either the 6-minute walk test (6MWT) or the 6MWT while wearing a dorsiflexion ankle
orthosis (with a randomised condition order). Distance walked, perceived exertion, perceived fatigue and the
physiological cost of walking (the primary outcome measures) will be compared between the two walking
conditions. Additional pre- and post-6MWT assessments for the two conditions will include tests of strength,
reaction time, gait and balance.
Discussion: This study will increase our understanding of motor fatigue on gait and balance control in PWMS and
elucidate the effect of a Dynamic Ankle Orthosis on fatigue-related balance and gait in PWMS. It will also examine
relationships between mobility and balance performance with perceived fatigue levels in this group.
Trial Registration Number: ACTRN12612000218897
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People with Multiple Sclerosis (PWMS) have difficulties
with gait and balance that can significantly limit activ-
ities of daily living and may increase the risk of falls [1].
Disruption to central nervous system integration of pro-
prioception, visual and vestibular sensory information
are all likely to contribute to balance problems and fall
risk in this population [1-3]. Perceived levels of fatigue
are also associated with balance problems and falls in
PWMS [4], while exercise-induced fatigue has been* Correspondence: james.mcloughlin@flinders.edu.au
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task [5].
Changes to gait can be detected early in the disease
course, even in PWMS without any mobility limitations
[6]. In fact, early gait and balance changes can be
detected in PWMS who have no pyramidal signs or clin-
ical disability [7]. These changes may be, in part, due to
lower limb motor fatigue, which is commonly reported
in PWMS and appears to worsen with increasing walk-
ing distance [8]. A previous study showed no significant
kinematic variability in gait with fatigue in a mildly dis-
abled group of PWMS [9]. However, fatigue related
changes in gait variability may become apparent inntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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Figure 1 Randomised cross-over trial design.
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alized fatigue in MS, our current understanding of
motor fatigue is limited. Ankle dorsifexors are particu-
larly susceptible to the effects of motor fatigue, with
both central and peripheral neuromuscular alterations
contributing to fatigue-related weakness [10].
In rehabilitation, treatments addressing dorsiflexion
weakness during gait can include specific dorsiflexor ex-
ercise and/or prescription of an Ankle Foot Orthoses
[11]. To date, studies have been unable to indicate the
effectiveness of these orthoses in improving ambulation
in PWMS [12]. Static and dynamic ankle foot orthoses
have been shown to improve static balance, but impair
dynamic balance when walking [13]. The Dorsiflexor As-
sist Orthosis (DAO) (Foot Up, Ossur©) differs from
standard ankle orthoses as it dynamically assists the foot
into dorsifexion with an elastic strap without affecting
the sensory input of the foot inside the shoe.
Moderately disabled ambulatory PWMS who have mo-
bility difficulties that impact on their ability to undertake
daily activities often seek outpatient or community
physiotherapy with the aim of improving or maintaining
mobility levels, but unfortunately, there is limited evi-
dence to inform clinicians with regard to best practice in
this area. The aim of this study, therefore, is to evaluate
the effect of a possible therapeutic device (i.e. a DAO)
on the six-minute walk test (6MWT), walking efficiency
and perceived levels of fatigue and exertion. The 6MWT
was selected as the fatiguing condition as it has been
evaluated in PWMS as a measure of functional capacity
and because PWMS have reduced 6MWT distance when
compared with controls [14]. In addition, we anticipate
that in a moderately disabled group, the 6MWT will in-
duce fatigue and changes to gait and balance control.
We will therefore examine any deterioration in function
by in gait patterns, balance and tests of motor function




A randomised cross-over trial will be conducted with 40
community-dwelling PWMS (Figure 1).
Participants
Participants will be recruited from the MS Society of
South Australia, the multidisciplinary MS Clinic at Re-
patriation General Hospital (RGH) and from private
physiotherapy clinics in South Australia. To be included,
participants must: (i) have a definite diagnosis of MS; (ii)
have mild to moderate difficulty in mobility with an
Expanded Disability Status Scale (EDSS) score of 3.0-6.0;
(iii) be able to walk for 6 minutes unaided or with the
aid of a walking stick. Participants will be excluded ifthey: (i) have had an exacerbation or relapse of MS
within the past 3 months; (ii) use medication prescribed
for fatigue or mobility such as Amantadine, Modafinil or
Fampridine; (iii) have significant cardiac or respiratory
disease; (iv) suffer from severe depression, or (v) have
arthritis, fibromyalgia or pain that severely limits walk-
ing. All participants will provide informed written con-
sent prior to involvement in the study. The Repatriation
General Hospital Research and Ethics Committee have
approved the study protocol, registration number
EC00191.
Setting/location
Assessments will take place at the South Australian
Movement Analysis Centre at the Repatriation General
Hospital, Adelaide.
Screening and initial assessments
Participants will initially be screened for disease severity
with the EDSS by a certified Neurostatus investigator
(www.neurostatus.net). Additional initial assessments
will include: (i) tests of vision, strength, balance, reaction
time and sensation [15]; (ii) measurements of height and
weight to calculate Body Mass Index (BMI); (iii) the
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tigue Impact Scale (MFIS) [17,18]; (v) the Beck Depres-
sion Inventory –Fast Screen (BDI-FS) [19]; and (vi) the
Multiple Sclerosis Walking Scale (MSWS-12) [20,21].
The walking protocol and Pre- and post-walk assessments
Following initial screening and assessments, participants
will be randomised with respect to condition order (i.e.
6MWT with or without DAO), and subsequently under-
take the baseline pre-walk assessments. Immediately fol-
lowing the 6MWT, participants will undertake the post-
walk assessments. The pre- and post-walk assessments
include tests of strength, simple reaction time, choice
stepping reaction time, standing balance, and gait ana-
lysis, as described below and presented in Figure 1. Par-
ticipants will return to the laboratory within 2 weeks to
complete the other 6MWT condition and associated
pre- and post-walk assessments.
Walking protocol & perceived exertion
Participants will wear a Polar heart rate monitor during
each walking condition. Participants will be seated at
rest for 2 minutes to determine a baseline heart rate. We
will use a modified 6MWT version from the American
Thoracic Society script with the aim of maximising ef-
fort and inducing fatigue [15]. Participants will be
instructed to walk back and forth along a ten-metre
walkway as fast as possible over the six-minute testing
period with the instructions “walk as fast as you com-
fortably can, bearing in mind that you will be walking
for 6 minutes”. Participants will be permitted to use as-
sistive devices (i.e. canes) if required. Distance walked
and perceived exertion will be recorded each minute
using the 10-point Modified Borg Rating of Perceived
Exertion (RPE) scale [16], and heart rate (beats/min) will
be automatically recorded at 5-second intervals. Physio-
logical Cost Index of walking will be calculated by the
formula;
average 6MWTHR average restingHRð Þ=walk speed;
where heart rate is measured in beats/min and walk
speed measured in m/min [17].
Perceived fatigue levels
Participants will be asked to indicate their perceived fa-
tigue levels will be measured using the Visual Analogue
Scale for Fatigue (VAS-F) [18] immediately before and
after the 6MWT.
3D Gait analysis
3D gait analysis will be conducted using an 8 camera
Vicon MX3 system (Vicon, Oxford, UK) with 4 AMTI
(AMTI, Watertown, MA) force plates and Helen Hayesmarker set [19]. Spatiotemporal data and kinematic and
kinetic data for the hip knee and ankle will be collected
over a minimum of 6 walking trials with and without the
DAO. Data will be collected using Vicon Nexus software
(v1.4) and processed with Matlab (v7.0). Sagittal plane
angles at the ankle are of particular interest, to examine
effects of the DAO, in addition to knee and hip angles to
identify potential compensations for DAO effects at the
ankle.
Strength
Knee extension and ankle dorsiflexion strength will be
determined as isometric force (kg) produced, measured
with a strain gauge linear to direction of force produc-
tion, normalised to body mass. Strength tests will be
conducted in a seated position. For knee strength test-
ing, the hip and knee will be positioned in 90 degrees of
flexion. The test of ankle strength will be conducted
with the ankle at 30 degrees of plantarflexion. Each
strength test will be repeated 3 times with sufficient rest
in between, and the maximum score recorded [20].
Simple reaction time
Participants will be seated in a chair with ceiling lights
dimmed. Simple reaction time will be measured in milli-
seconds using a handheld electronic timer, with partici-
pants seated and using a light as the stimulus and a
finger-press (hand reaction time) or a foot-press (foot re-
action time) as the response. Five practice trials will be
followed by an additional 10 trials, for which reaction
time in milliseconds will be recorded for each trial and
averaged [20].
Choice stepping reaction time (CSRT)
The CSRT device consists of a floor-mounted mat that
contains six plates (32 X 13 cm): two base plates on
which the participant stands and four target plates. A
computer monitor displays a corresponding image of the
mat. One of the stepping plates on the computer image
light up in a random order. The participant will be
instructed to step on to the corresponding illuminated
plate as quickly as possible, using their left foot for the
targets to the left and to the front left, and their right for
the targets to their right and front right. Reaction times
for (i) time to lift the foot from the base plate and (ii)
time to land the foot on target plate will be recorded.
Each plate will be presented 5 times, and sufficient time
will be given between each trial to re-establish balance
and minimise fatigue [21,22].
Standing balance
Standing balance will be measured while participants
stand on two AMTI force plates. Postural position of C7
and sacrum will be measured using reflective markers
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will stand for 30 seconds under 4 conditions: (i) eyes
open feet apart; (ii) eyes open feet together; (iii) eyes
closed feet apart; and (iv) eyes closed feet together. Each
condition will be repeated with the 8 trials presented in
a randomized order.
Primary outcome measures
The primary outcome measures are walking distance,
physiological cost index and perceived fatigue and exer-
tion during the 6MWT.
Secondary outcome measures
The secondary outcome measures are hand and foot
simple reaction time, choice stepping reaction time, knee
extension and ankle dorsiflexion strength, postural sway
with feet together and apart and the spatio-temporal,
kinematic and kinetic gait parameters.
Sample size calculations
We used the “Inequality Tests for Two Means in a 2x2
Cross-Over Design using Differences” module from the
Power Analysis and Sample Size (PASS) software [18]
for estimating the sample size required for the primary
outcome measure of 6MWT distance. The following
parameters were entered into the calculation: power =
0.8; alpha = 0.05; N(total sample size) = 20,30,40; mean
difference between groups at retest = .50,100,150. Stand-
ard deviation measures were estimated from previous
studies [11]. The difference in 6MWT distance was
based on the rationale that a clinically meaningful in-
crease in metres walked by MS patients in this test is
100 m (i.e. the difference reported between Mild MS
and Moderate MS [23]). These analyses indicated that a
sample size of 35 would be appropriate for the study de-
sign. An additional 5 participants will be recruited to
allow for possible dropouts.
Statistical analysis
Initially we will examine the frequency distributions,
percentages and calculate means and standard deviations
(mean +/−SD) for the outcome measures. Repeated
measures analysis of variance (ANOVA) will be used to
determine differences in the outcome measures with
time and DAO condition as factors. Finally, we will
examine associations between 6MWT and measures of
fatigue (FSS, MFIS VAS-F & Borg RPE), EDSS scores
and Postural Sway data with Pearson correlations. The
data will be analysed with the Statistical Package for So-
cial Science (SPSS) software.
We will adjust for other possible confounding vari-
ables by using a covariance analysis. Multiple regression
analysis will be used to examine significant, independent
predictors of 6MWT distance.Discussion
This study will examine the use of a novel ankle dorsi-
flexion assisting device (DAO) on walking performance
in people with moderate MS and determine potential
beneficial effects on walking induced changes in fatigue,
gait patterns, strength, balance and reaction time. Am-
bulation distance has historically been a key measure of
functional status and disability in PWMS [24]. A recent
multidisciplinary consensus conference in 2007, with the
Consortium of MS Centres in the USA, agreed that re-
habilitation professionals need to improve their under-
standing of gait and fatigue outcome measures used in
MS rehabilitation [22].
While it is known that PWMS have reduced mobility,
impaired balance and higher fatigue levels compared
with healthy controls, the complex interaction between
these factors is not well understood. PWMS have a
reduced 6MWT performance compared to healthy con-
trols, and it is important to identify the changes in fa-
tigue, gait, balance and motor function that result in this
reduced mobility as this may identify key modifiable tar-
gets for rehabilitation. These targets may include either
exercise and/or timely use of specific orthoses to maxi-
mise functional mobility while reducing the risk of falls.
We believe this detailed study design will allow us to
further determine what kinematic and kinetic changes
are associated with prolonged walking in PWMS, pro-
viding a more detailed understanding of complex move-
ment dysfunctions such as spasticity and localised motor
fatigue. This may also help in designing individualised
orthoses aimed at maximising mobility without com-
promising balance control. In addition we hope to
deepen our knowledge of perceived fatigue and physio-
logical performance associated with mobility.
It is likely a rehabilitation approach that uses exercises
that address aspects of strength and skilled recruitment
of muscles involved in walking and dynamic balance
may need to be combined with individually prescribed
orthoses in order to maximise mobility for PWMS. Our
ability to analyse gait and balance becomes increasingly
important when considering recent therapeutic advance-
ments that have been shown to reduce clinical progres-
sion, improve disability and increase ambulation levels
[25,26]. This is an important step for future research
directed towards evaluating targeted interventions for
improving balance and mobility and reducing fatigue in
PWMS.Abbreviations
PWMS: People with Multiple Sclerosis; 6MWT: Six-Minute Walk Test;
DAO: Dynamic Ankle Orthosis; RGH: Repatriation General Hospital;
EDSS: Expanded Disability Status Scale; MS: Multiple Sclerosis; BMI: Body Mass
Index; FSS: Fatigue Severity Scale; MFIS: Modifies Fatigue Impact Scale; BDI-
FS: Beck Depression Inventory- Fast Scale; MSWS-12: Multiple Sclerosis
Walking Scale; RPE: Rating of Perceived Exertion; VAS-F: Visual Analogue
McLoughlin et al. BMC Neurology 2012, 12:27 Page 5 of 5
http://www.biomedcentral.com/1471-2377/12/27Scale for Fatigue; CSRT: Choice Stepping Reaction Time; PASS: Power Analysis
and Sample Size; ANOVA: Analysis of Variance.
Competing Interests
The Physiological Profile Assessment (FallScreen) is commercially available
through Neuroscience Research Australia.
Authors’ contributions
JMcL SL DS and MC conceived the idea. All authors obtained funding for the
study. All authors contributed to the design and development of the trial
protocol. JMcL, CB& DS drafted the manuscript. All authors critically reviewed
the manuscript and approved the final manuscript.
Acknowledgements
The project is funded by the Multiple Sclerosis Research Australia and
Foundation Daw Park.
Author details
1Flinders University South Australia, GPO Box 2100, Adelaide 5001, Australia.
2Neuroscience Research Australia, PO Box 1165 Randwick, NSW 2031
Australia. 3University of New South Wales, Sydney, NSW 2052 Australia.
Received: 23 February 2012 Accepted: 25 May 2012
Published: 25 May 2012
References
1. Peterson EW, Cho CC, von Koch L, Finlayson ML: Injurious falls among
middle aged and older adults with multiple sclerosis. Arch Phys Med
Rehabil 2008, 89(6):1031–1037.
2. Nelson SR, Di Fabio RP, Anderson JH: Vestibular and sensory interaction
deficits assessed by dynamic platform posturography in patients with
multiple sclerosis. Ann Otol Rhinol Laryngol 1995, 104(1):62–68.
3. Cattaneo D, Jonsdottir J: Sensory impairments in quiet standing in
subjects with multiple sclerosis. Mult Scler 2009, 15(1):59–67.
4. Nilsagard Y, Lundholm C, Denison E, Gunnarsson LG: Predicting accidental
falls in people with multiple sclerosis – a longitudinal study. Clin Rehabil
2009, 23(3):259–269.
5. Van Emmerik RE, Remelius JG, Johnson MB, Chung LH, Kent-Braun JA:
Postural control in women with multiple sclerosis: Effects of task, vision
and symptomatic fatigue. Gait Posture 2010, 32(4):608–614.
6. Benedetti MG, Piperno R, Simoncini L, Bonato P, Tonini A, Giannini S: Gait
abnormalities in minimally impaired multiple sclerosis patients. Mult Scler
1999, 5(5):363–368.
7. Martin CL, Phillips BA, Kilpatrick TJ, Butzkueven H, Tubridy N, McDonald E,
Galea MP: Gait and balance impairment in early multiple sclerosis in the
absence of clinical disability. Mult Scler 2006, 12(5):620–628.
8. Schwid SR, Thornton CA, Pandya S, Manzur KL, Sanjak M, Petrie MD,
McDermott MP, Goodman AD: Quantitative assessment of motor fatigue
and strength in MS. Neurology 1999, 53(4):743–750.
9. Crenshaw SJ, Royer TD, Richards JG, Hudson DJ: Gait variability in people
with multiple sclerosis. Mult Scler 2006, 12(5):613–619.
10. Ng AV, Miller RG, Gelinas D, Kent-Braun JA: Functional relationships of
central and peripheral muscle alterations in multiple sclerosis. Muscle
Nerve 2004, 29(6):843–852.
11. Mount J, Dacko S: Effects of dorsiflexor endurance exercises on foot drop
secondary to multiple sclerosis: a pilot study. NeuroRehabilitation 2006, 21
(1):43–50.
12. Sheffler LR, Hennessey MT, Knutson JS, Naples GG, Chae J: Functional effect
of an ankle foot orthosis on gait in multiple sclerosis: a pilot study. Am J
Phys Med Rehabil 2008, 87(1):26–32.
13. Cattaneo D, Marazzini F, Crippa A, Cardini R: Do static or dynamic AFOs
improve balance? Clin Rehabil 2002, 16(8):894–899.
14. Savci S, Inal-Ince D, Arikan H, Guclu-Gunduz A, Cetisli-Korkmaz N, Armutlu K,
Karabudak R: Six-minute walk distance as a measure of functional
exercise capacity in multiple sclerosis. Disabil Rehabil 2005,
27(22):1365–1371.
15. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit
Care Med 2002, 166(1):111–117.
16. Borg GA: Psychophysical bases of perceived exertion. Medicine and
science in sports and exercise 1982, 14(5):377–381.17. Jaiyesimi AO, Fashakin OG: Reliability of physiological cost index
measurements. Afr J Med Med Sci 2007, 36(3):229–234.
18. Lee KA, Hicks G, Nino-Murcia G: Validity and reliability of a scale to assess
fatigue. Psychiatry Res 1991, 36(3):291–298.
19. Kadaba MP, Ramakrishnan HK, Wootten ME: Measurement of lower
extremity kinematics during level walking. J Orthop Res 1990,
8(3):383–392.
20. Lord SR, Menz HB, Tiedemann A: A physiological profile approach to falls
risk assessment and prevention. Phys Ther 2003, 83(3):237–252.
21. St George RJ, Fitzpatrick RC, Rogers MW, Lord SR: Choice stepping
response and transfer times: effects of age, fall risk, and secondary tasks.
J Gerontol A Biol Sci Med Sci 2007, 62(5):537–542.
22. Sturnieks DL, St George R, Fitzpatrick RC, Lord SR: Effects of spatial and
nonspatial memory tasks on choice stepping reaction time in older
people. J Gerontol A Biol Sci Med Sci 2008, 63(10):1063–1068.
23. Goldman M, Ann Marrie R, Cohen JA: Evaluation of the six-minute walk in
multiple sclerosis subjects and healthy controls. Mult Scler 2008, 14
(3):383–390.
24. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an
expanded disability status scale (EDSS). Neurology 1983, 33(11):1444–1452.
25. Belachew S, Phan-Ba R, Bartholome E, Delvaux V, Hansen I, Calay P, Hafsi KE,
Moonen G, Tshibanda L, Vokaer M: Natalizumab induces a rapid
improvement of disability status and ambulation after failure of previous
therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2011, 18
(2):240–245.
26. Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R,
Marinucci LN, Blight AR: Sustained-release oral fampridine in multiple
sclerosis: a randomised, double-blind, controlled trial. Lancet 2009, 373
(9665):732–738.
doi:10.1186/1471-2377-12-27
Cite this article as: McLoughlin et al.: Effect of wearing a dorsiflexion
assist orthosis on mobility, perceived fatigue and exertion during the
six-minute walk test in people with multiple sclerosis: a randomised
cross-over protocol. BMC Neurology 2012 12:27.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
